M5C Methylation Modification May Be an Accomplice in Colorectal Cancer Escaping from Anti-tumor Effects of Innate Immunity-type I/III Interferon

Overview

Journal Front Immunol

Date 2025 Jan 27

PMID 39867908

Authors

Yiqi Sun

Yunfei Liu

Lu Jiang

Chao Zhong

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is one of the most prevalent malignant tumors in the world, and its occurrence and development are closely related to the complex immune regulatory mechanisms. As the first barrier of the body's defense, innate immunity plays a key role in tumor immune surveillance and anti-tumor response, in which type I/III interferon (IFN) is an important mediator with significant antiviral and anti-tumor functions. 5-methylcytosine (m5C) modification of RNA is a key epigenetic regulation that promotes the expression of CRC oncogenes and immune-related genes. It can enhance the proliferation, migration, and invasion of tumor cells by affecting mRNA stability, translation efficiency, and nuclear export. In addition, m5C modification modulates the activity of innate immune signaling pathways and inhibits interferon production and function, further helping tumor cells evade immune surveillance. However, there are insufficient elucidations on the interaction between m5C modification and innate immunity in CRC. In this study, the mechanism of interferon I/III in colorectal cancer was systematically reviewed and explored. This work focused on how m5C modification promotes tumor immune escape by affecting the interferon signaling pathway, thereby providing new diagnostic markers and therapeutic targets for clinical use, and enhancing the immunotherapy efficacy.

References

Zhu J, Liu S, Fang J, Cui Z, Wang B, Wang Y . Enzymolysis-based RNA pull-down identifies YTHDC2 as an inhibitor of antiviral innate response. Cell Rep. 2023; 42(10):113192. DOI: 10.1016/j.celrep.2023.113192. View

Katlinski K, Gui J, Katlinskaya Y, Ortiz A, Chakraborty R, Bhattacharya S . Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell. 2017; 31(2):194-207. PMC: 5313042. DOI: 10.1016/j.ccell.2017.01.004. View

Zhou Y, Ji M, Xia Y, Han X, Li M, Li W . Silencing of IRF8 Mediated by m6A Modification Promotes the Progression of T-Cell Acute Lymphoblastic Leukemia. Adv Sci (Weinh). 2022; 10(2):e2201724. PMC: 9839875. DOI: 10.1002/advs.202201724. View

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

Song J, Zhao W, Zhang X, Tian W, Zhao X, Ma L . Mutant RIG-I enhances cancer-related inflammation through activation of circRIG-I signaling. Nat Commun. 2022; 13(1):7096. PMC: 9675819. DOI: 10.1038/s41467-022-34885-3. View

Brown J, Wang H, Hajishengallis G, Martin M . TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J Dent Res. 2010; 90(4):417-27. PMC: 3075579. DOI: 10.1177/0022034510381264. View

Liu C, Du X, Zhou X, Kolosov V, Perelman J . MicroRNA-155 regulates lipopolysaccharide-induced mucin 5AC overproduction via a suppressor of cytokine signaling 1-mediated mechanism in human bronchial epithelial cells. Respir Physiol Neurobiol. 2019; 264:12-18. DOI: 10.1016/j.resp.2019.03.008. View

Chen B, Xi Y, Zhao J, Hong Y, Tian S, Zhai X . m5C regulator-mediated modification patterns and tumor microenvironment infiltration characterization in colorectal cancer: One step closer to precision medicine. Front Immunol. 2022; 13:1049435. PMC: 9751490. DOI: 10.3389/fimmu.2022.1049435. View

Taguchi T, Mukai K . Innate immunity signalling and membrane trafficking. Curr Opin Cell Biol. 2019; 59:1-7. DOI: 10.1016/j.ceb.2019.02.002. View

10.

Chen J, Markelc B, Kaeppler J, Ogundipe V, Cao Y, McKenna W . STING-Dependent Interferon-λ1 Induction in HT29 Cells, a Human Colorectal Cancer Cell Line, After Gamma-Radiation. Int J Radiat Oncol Biol Phys. 2018; 101(1):97-106. DOI: 10.1016/j.ijrobp.2018.01.091. View

11.

Yi M, Li T, Niu M, Mei Q, Zhao B, Chu Q . Exploiting innate immunity for cancer immunotherapy. Mol Cancer. 2023; 22(1):187. PMC: 10680233. DOI: 10.1186/s12943-023-01885-w. View

12.

Phillip West A, Khoury-Hanold W, Staron M, Tal M, Pineda C, Lang S . Mitochondrial DNA stress primes the antiviral innate immune response. Nature. 2015; 520(7548):553-7. PMC: 4409480. DOI: 10.1038/nature14156. View

13.

Maiorino L, Dassler-Plenker J, Sun L, Egeblad M . Innate Immunity and Cancer Pathophysiology. Annu Rev Pathol. 2021; 17:425-457. PMC: 9012188. DOI: 10.1146/annurev-pathmechdis-032221-115501. View

14.

Jin B, Chung K, Hwang S, Hwang S, Rhee K, Lee M . Rosmarinic acid represses colitis-associated colon cancer: A pivotal involvement of the TLR4-mediated NF-κB-STAT3 axis. Neoplasia. 2021; 23(6):561-573. PMC: 8180929. DOI: 10.1016/j.neo.2021.05.002. View

15.

Ye L, Schnepf D, Staeheli P . Interferon-λ orchestrates innate and adaptive mucosal immune responses. Nat Rev Immunol. 2019; 19(10):614-625. DOI: 10.1038/s41577-019-0182-z. View

16.

Snell L, McGaha T, Brooks D . Type I Interferon in Chronic Virus Infection and Cancer. Trends Immunol. 2017; 38(8):542-557. PMC: 8059441. DOI: 10.1016/j.it.2017.05.005. View

17.

Zhou J, Zhang X, Hu J, Qu R, Yu Z, Xu H . mA demethylase ALKBH5 controls CD4 T cell pathogenicity and promotes autoimmunity. Sci Adv. 2021; 7(25). PMC: 8208713. DOI: 10.1126/sciadv.abg0470. View

18.

Walker F, Sridhar P, Baldridge M . Differential roles of interferons in innate responses to mucosal viral infections. Trends Immunol. 2021; 42(11):1009-1023. PMC: 8496891. DOI: 10.1016/j.it.2021.09.003. View

19.

Yang L, Zhang X, Huang X, Dong X, Jing S, Zhang Y . Correlation between IFNAR1 expression in peripheral blood T lymphocytes and inflammatory cytokines, tumor-infiltrating lymphocytes, and chemosensitivity in patients with colorectal cancer. Cytokine. 2022; 159:156008. DOI: 10.1016/j.cyto.2022.156008. View

20.

Katayama T, Nakanishi K, Nishihara H, Kamiyama N, Nakagawa T, Kamiyama T . Type I interferon prolongs cell cycle progression via p21WAF1/CIP1 induction in human colon cancer cells. Int J Oncol. 2007; 31(3):613-20. View